Renal cell carcinoma in patients receiving hemodialysis treatment

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. In patients with end-stage renal disease (esrd), renal cell carcinoma (rcc) is detected more often than in the general population. in order to improve the results of treatment of patients in this category, we conducted a retrospective analysis of our own experience. material and methods. During the period from 2010 to 2020, nephrectomy (ne) for rcc was performed in 26 patients treated with hemodialysis (hd) at the city clinical hospital №52 of the moscow healthcare department. To identify predictors of rcc, 100 patients treated with hd during the indicated period were randomly selected as a control group. results. significant risk factors for rcc were only male gender (aor 5.1; 95% cl 1.34-14.4; p=0.015) and the presence of multiple kidney cysts (or=3.2, 95% cl 1.56-16, 43; p=0.008). A bimodal increase in the frequency of rcc was noted: in the first year after the onset of hd and 5 years later. after ne, bleeding due to systemic hypocoagulation was registered only in one case. hyperkalemia was noted in 5 (19.2%) patients immediately after laparoscopic ne. Based on the tnm stage, the uicc (university of california los angeles integrated staging system) nomogram, and the leibovich score, a favorable oncological prognosis was noted in 17 (65.4%) patients. the median follow-up of patients after ne was 20 months (q1-q3: 8.5-45), with a minimum of 2 months and a maximum of 72 months. In none of the cases progression of rcc was noted. Conclusion. the high-risk group for developing rcc was male patients with multiple kidney cysts. After laparoscopic ne, monitoring of blood potassium levels is required. The vast majority of patients after surgical treatment were characterized by a favorable oncological prognosis and they could be considered for kidney transplantation without an additional period of follow-up.

Full Text

Restricted Access

About the authors

Aleksandr E. Lubennikov

City Clinical Hospital №52 of the Moscow Healthcare Department

Email: lualev@yandex.ru
Dr. Sci. (Med.), Urologist, Urology Department Moscow, Russia

Ruslan N. Trushkin

City Clinical Hospital №52 of the Moscow Healthcare Department

Email: uro52@mail.ru
Dr.Sci. (Med.), Head of the Department of Urology Moscow, Russia

Elvira E. Berezhnaya

City Clinical Hospital №52 of the Moscow Healthcare Department

Pathologist Moscow, Russia

Teymur K. Isaev

City Clinical Hospital №52 of the Moscow Healthcare Department

Email: dr.isaev@mail.ru
Cand. Sci. (Med.), Urologist, Urology Department Moscow, Russia

Nikolay V. Morozov

City Clinical Hospital №52 of the Moscow Healthcare Department

Email: nikmorozov@rambler.ru
Urologist, Urology Department Moscow, Russia

Pavel E. Medvedev

City Clinical Hospital №52 of the Moscow Healthcare Department

Email: pah95@mail.ru
Urologist, Urology Department Moscow, Russia

Nikolai O. Kolesnikov

City Clinical Hospital №52 of the Moscow Healthcare Department

Email: knikolai@list.ru
Urologist, Urology Department Moscow, Russia

References

  1. Hurst F.P., Jindal R.M., Fletcher J.J., et al. Incidence, predictors and associated outcomes of renal cell carcinoma in long-term dialysis patients. Urol. 2011;77(6):1271-76. doi: 10.1016/j.urology.2011.01.007.
  2. Stewart J.H., Buccianti G., Agodoa L., et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J. Am. Soc. Nephrol. 2003;14(1):197-207. doi: 10.1097/01.asn.0000039608.81046.81.
  3. Engels E.A., Pfeiffer R.M., Fraumeni J.F., et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-901. doi: 10.1001/jama.2011.1592.
  4. Holley J.L. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin. J. Am. Soc. Nephrol. 2007;2(3):604-10. Doi: 10.2215/ CJN.03931106.
  5. Lutz J., Menke J., Sollinger D., et al. Haemostasis in chronic kidney disease. Nephrol. Dial. Transplant. 2014;29(1):29-40. doi: 10.1093/ndt/gft209.
  6. Acedillo R.R., Shah M., Devereaux P.J., al. The risk of perioperative bleeding in patients with chronic kidney disease: a systematic review and meta-analysis. Ann. Surg. 2013;258(6):901-13. doi: 10.1097/SLA.0000000000000244.
  7. Sanli O., Tefik T., Ortac M., et al. Laparoscopic nephrectomy in patients undergoing hemodialysis treatment. JSLS. 2010;14(4):534-40. Doi: 10.4293/ 108680810X12924466008123.
  8. Frasca G.M., Brigante F., Volpe A., et al. Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. J. Nephrol. 2019;32(1):57-64. doi: 10.1007/s40620-018-0542-y.
  9. Boissier R., Hevia V., Bruins H.M., et al. The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. Eur. Urol. 2018;73(1):94-108. doi: 10.1016/j.eururo.2017.07.017.
  10. Cognard N., Anglicheau D., Gatault P., et al. Recurrence of Renal Cell Cancer After Renal Transplantation in a Multicenter French Cohort. Transplantat. 2018;102(5):860-67. doi: 10.1097/TP.0000000000002009.
  11. Bellido J.A., Palou J., Htibner M., et al. Early ultrasound detection of renal tumors in patients with end stage renal disease in dialysis. Arch. Esp. Urol. 2007;60(9):1079-83. doi: 10.4321/s0004-06142007000900004.
  12. Jung S.H., Han Y.J., Shin S.H., et al. Sudden Intraoperative Hyperkalemia during Laparoscopic Radical Nephrectomy in a Patient with Underlying Renal Insufficiency. Acute Crit. Care. 2018;33(4):271-75. doi: 10.4266/acc.2016.00696.
  13. Keehn A., Maiman R., Agalliu I., et al. Outcomes and Management Considerations in Patients on Dialysis Undergoing Laparoscopic Radical Nephrectomy for Renal-Cell Carcinoma. J. Endourol. 2015;29(6):691-95. doi: 10.1089/end.2014.0484.
  14. Novara G., Ficarra V., Antonelli A., et al. Corrigendum to “Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: Are further improvements needed?” Eur. Urol. 2010;58:588-95. doi: 10.1016/j.eururo.2010.10.017.
  15. Klatte T., Chung J., Leppert J.T., et al. Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU.Int. 2007;99(4):821-24. doi: 10.1111/j.1464-410X.2006.06729.x.
  16. Wagener N., Edelmann D., Benner A., et al. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. PLoS. One. 2017;12(9):e0184173. doi: 10.1371/journal.pone.0184173.
  17. Cheville J.C., Lohse C.M., Zincke H., et al.Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 2003;27(5):612-24. doi: 10.1097/00000478-200305000 00005.
  18. Leibovich B.C., Lohse C.M., Crispen P.L., et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J. Urol. 2010;183(4):1309-15. doi: 10.1016/j.juro.2009.12.035.
  19. Moch H., Cubilla A.L., Humphrey P.A., et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur. Urol. 2016;70(1):93-105. doi: 10.1016/j.eururo.2016.02.029.
  20. Zhang B.Y., Cheville J.C., Thompson R.H., et al. Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma. Eur. Urol. 2015;68(1):5-7. doi: 10.1016/j.eururo.2015.01.002.
  21. Lang H., Lindner V., de Fromont M., et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: Assessment of 241 patients with >15-year follow-up. Cancer. 2005;103(3):625-29. doi: 10.1002/cncr.20812.
  22. Sorbellini M., Kattan M.W., Snyder M.E., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J. Urol. 2005;173(1):48-51. doi: 10.1097/01. ju.0000148261.19532.2c.
  23. Patard J.J., Kim H.L., Lam J.S., et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. 2004;22(16):3316-22. doi: 10.1200/JCO.2004.09.104.
  24. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663-71. doi: 10.1002/cncr.11234.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies